All terms and conditions of Roche's offer remain unchanged, it said in a statement on Monday.
(Reporting by John Miller; editing by Thomas Seythal)
Swiss drugmaker Roche again extended its offer for shares of gene therapy specialist Spark Therapeutics to Dec. 16 as a regulatory review of the $4.3 billion (3.35 billion pounds) transaction drags on.
All terms and conditions of Roche's offer remain unchanged, it said in a statement on Monday.
(Reporting by John Miller; editing by Thomas Seythal)
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
396 USD | +2.18% | +0.34% | 108B | ||
214.1 CHF | -2.95% | -6.79% | 194B | ||
99.2 CHF | -0.62% | -2.60% | 31.53B | ||
1st Jan change | Capi. | |
---|---|---|
-1.65% | 104B | |
+6.75% | 97.47B | |
+5.71% | 22.25B | |
-12.60% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.17% | 16.36B | |
+6.12% | 14.39B | |
+35.47% | 12.37B |